ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01298921
Recruitment Status : Unknown
Verified March 2012 by Geisinger Clinic.
Recruitment status was:  Recruiting
First Posted : February 18, 2011
Last Update Posted : March 16, 2012
Sponsor:
Information provided by (Responsible Party):
Geisinger Clinic

February 16, 2011
February 18, 2011
March 16, 2012
January 2011
October 2012   (Final data collection date for primary outcome measure)
Reduction in headache pain [ Time Frame: 30 minutes ]
Headache response after 30 minutes of oxygen treatment. Headache response is defined as a reduction in headache pain intensity from moderate, severe, or very severe pain to mild or no pain.
Same as current
Complete list of historical versions of study NCT01298921 on ClinicalTrials.gov Archive Site
Headache relief and pain free [ Time Frame: 5 to 60 minutes ]
  1. Percentage of patients with no pain after 30 minutes of treatment
  2. Headache relief and pain free at other time points (5 to 60 minutes)
  3. Reduction of autonomic symptoms at 30 minutes
  4. Any difference in treatment response between episodic and chronic cluster headache patients (if patient #'s allow)
  5. Rescue medication use
  6. Cluster headache recurrence by 24 hours post oxygen treatments
  7. Patient satisfaction with treatment response compared with prior oxygen treatment if have utilized8.Likelihood of choosing this technique again to treat a cluster headache attack
Same as current
Not Provided
Not Provided
 
A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache
A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache

Cluster headache is a disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. It is the most severe head pain syndrome known. Currently, the two most common treatments for cluster headaches are inhaled oxygen and injectable sumatriptan. These treatments do not work for all cluster headache patients, and patients who smoke may eventually develop contraindication to triptans. New treatment options are needed.

An alternative method of oxygen delivery (as opposed to continuous flow) uses a demand valve that is controlled by respiration rate, allowing increased oxygen flow in response to increased demand. This system may be more efficacious at stopping a cluster headache attack than the currently prescribed oxygen delivery system.

This study will compare the effectiveness of oxygen delivered via demand valve versus continuous high flow oxygen via non-rebreather face mask in the acute treatment of a cluster headache attack. All patients will treat one cluster headache with each of the 2 treatment methods.

Cluster headache is a primary headache disorder marked by frequent attacks of short-lasting, severe, unilateral head pain with associated autonomic symptoms. The goal of acute therapy for cluster headache is fast, effective and consistent relief.

In the currently recommended dosing strategy of continuous flow 100% oxygen given via a non-rebreather face mask at 7-15L/min, the time to improvement can sometimes take upwards of 20-30 minutes and is not effective for all cluster headache sufferers.

An alternative method of oxygen delivery (versus continuous flow) uses a demand valve which is controlled by the respiration rate, allowing increased oxygen flow in response to increased demand. This delivery system may be better at stopping a cluster headache attack than the continuous flow model as it can support hyperventilation which can enhance cerebral arterial vasoconstriction via a state of hyperoxia and hypocapnia. Arterial vasoconstriction is one hypothesized method by which oxygen can abort a cluster headache attack.

This proof of concept trial will evaluate if oxygen delivered via demand valve with a specific breathing technique is effective as a cluster headache acute treatment and is more effective than the traditional continuous high flow oxygen treatment with a non-rebreather face mask.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Cluster Headache
  • Drug: Oxygen
    A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
  • Drug: Oxygen
    100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
  • Active Comparator: Continous Flow Oxygen
    Intervention: Drug: Oxygen
  • Experimental: Oxygen Demand Valve
    Intervention: Drug: Oxygen
Rozen TD, Fishman RS. Demand valve oxygen: a promising new oxygen delivery system for the acute treatment of cluster headache. Pain Med. 2013 Apr;14(4):455-9. doi: 10.1111/pme.12055. Epub 2013 Jan 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
12
Same as current
November 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men or women 18 to 65 with history of moderate severe or very severe cluster headaches and currently in a cluster headache period or cycle are included.

Exclusion Criteria:

  • Subjects who have a history of chronic obstructive lung disease, those who have major neurologic disorders other than cluster headaches, those with a history of syncope, or lightheadedness with hyperventilation and pregnant women are excluded.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01298921
2010-0205
No
Not Provided
Not Provided
Geisinger Clinic
Geisinger Clinic
Not Provided
Principal Investigator: Todd D. Rozen, MD Geisinger Clinic
Geisinger Clinic
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP